Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
SJ Reshkin, RA Cardone, T Koltai - Cells, 2024 - mdpi.com
Pancreatic cancer is a highly lethal disease with a 5-year survival rate of around 11–12%.
Surgery, being the treatment of choice, is only possible in 20% of symptomatic patients. The …
Surgery, being the treatment of choice, is only possible in 20% of symptomatic patients. The …
Dual-hit strategy for therapeutic targeting of pancreatic cancer in patient-derived xenograft tumors
T Roy Chaudhuri, Q Lin, EK Stachowiak… - Clinical Cancer …, 2024 - AACR
Purpose: Paracrine activation of pro-fibrotic hedgehog (HH) signaling in pancreatic ductal
adenocarcinoma (PDAC) results in stromal amplification that compromises tumor drug …
adenocarcinoma (PDAC) results in stromal amplification that compromises tumor drug …
Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness
Aims Pancreatic ductal adenocarcinoma (PDAC) is often intrinsically-resistant to standard-of-
care chemotherapies such as gemcitabine. Acquired gemcitabine resistance (GemR) can …
care chemotherapies such as gemcitabine. Acquired gemcitabine resistance (GemR) can …